Hoʻokahi ʻanuʻu kokoke i ka lāʻau lapaʻau hou no Cystic Fibrosis

Ua hoʻolaha ʻo Entrinsic Bioscience a me kāna mea laikini ʻo Nuvara Therapeutics ua kokoke lākou i ka hoʻohana ʻana i nā formulations RxAA ma ke ʻano he lāʻau lapaʻau no nā maʻi me ka Cystic Fibrosis Class I mutations. ʻO ka mea noiʻi o ke Kulanui o Florida ʻo Dr. Sadasivan Vidyasagar, ka mea nāna i hoʻokumu a me ka luna hoʻomalu o ka papa ʻōlelo aʻoaʻo ʻepekema o ka hui, ua haʻi aku nei i kahi ala ʻē aʻe e hoʻihoʻi ai i ka huna ʻana o ka anion ea ma ka hālāwai Experimental Biology 2022 i mālama ʻia ma Philadelphia.      

Ua hōʻike ʻo Vidyasagar a me kāna hui, ʻo ia hoʻi nā mea noiʻi mai UF a me Entrinsic Bioscience, hiki i ka Nuvara's VS-009 formula ke kōkua i nā poʻe maʻi me Cystic Fibrosis Class I mutations a me ka Class II a me III mutations. Hiki ke hoʻohana wale ʻia ka lāʻau lapaʻau a i hui pū ʻia me nā lāʻau lapaʻau ʻē aʻe e hoʻomaikaʻi ai i ka huna ʻana o ka chloride.

Ua hoʻomaikaʻi ʻo Stephen J. Gatto, Luna Hoʻokele o Nuvara Therapeutics, iā Astrid Grosche a me ke koena o ka hui o Kauka Vidyasagar no kā lākou hoʻomau mau ʻana i ka hoʻokele ʻana i nā ala hou e loiloi i ka hana epithelial respiratory.

"Makemake au e hoʻomaikaʻi aku iā Astrid, Kauka Vidyasagar a me nā mea ʻē aʻe o kāna hui no kā lākou hoʻokō luhi ʻole e hoʻoponopono i nā hoʻololi ʻana o ka Class I ma Cystic Fibrosis, kahi hoʻololi e hiki ke hoʻopili i ka 18% o ka heluna kanaka CF," wahi a Stephen J. Gatto.

"Ke hōʻike nei kēia mau abstract ʻelua e hiki ke hoʻopololei i ka ion-channel i loko o ka epithelium hanu me ka hoʻohana ʻana i nā hoʻohālikelike ʻia o nā waikawa amino," i hoʻomau ai ʻo Gatto. "ʻO ka maʻi ion-channel ke kikowaena o nā maʻi he nui, e like me CF a me nā maʻi i hoʻonui ʻia ai ka hana mucous, me ka hānō a me COPD. ʻO kēia mau ala / lapaʻau e ʻae iā mākou e hoʻololi i ka komo ʻana o nā ion a me ka wai i ke alaloa ma kahi pae kelepona me nā hopena liʻiliʻi.

"Aia nō ka hana e hana ʻia, akā he mea hoihoi maoli ka manawa a hiki ke hōʻike i kahi holomua i ka hoʻokele ʻana i nā channelopathies a me nā maʻi pili," wahi a Gatto.

Ua hōʻike pū ʻo Vidyasagar i kahi paʻi ma luna o kahi mea hana i kūkulu ʻia e kāna lab e ana ʻoi aku ka maikaʻi o ke ana ʻana i ka peristalsis o ka ʻōpū a me nā pilina o ke kaomi intraluminal, ka ʻoki ʻana o ka ʻiʻo, a me nā loli i ka nui o ka wai.

"He ʻokoʻa kēia mau abstracts ʻelua i ka mea e hōʻike ana i ka hiki ke hoʻololi i nā protein transmembrane epithelial (eTMPs) me kahi hoʻonohonoho koho o amino SAA (RxAAs)," wahi a Kauka William Denman, Luna Hoʻokele Lapaʻau Nui i Nuvara Therapeutics. "Wehe kēia i ka puka no ka lāʻau lapaʻau maikaʻi ʻole i ka pae cellular maʻamau, me ka ʻole o ka etiology."

Ua hoʻomau ʻo Kauka Denman, "E hoʻoholo ʻia nā lāʻau i ka wā e hiki mai ana i kēia manawa a hoʻopaʻa ʻia no ke kahawai a me ka maʻi - ka lāʻau lapaʻau pilikino maoli. Pono nā hana hou aʻe, akā hiki i kēia ke ʻae i nā koho lapaʻau ma kahi pae kelepona ma waena o nā spectrum maʻi me nā hopena ʻaoʻao liʻiliʻi.

ʻO Entrinsic Bioscience kahi hoʻomaka UF aia ma UF Innovate | E holo wikiwiki ma Sid Martin Biotech ma Alachua. Ke hoʻomohala nei ka hui i nā mea kūlohelohe āpau, glucose-free formulations no ka hydration clinical, ke olakino ʻōpū a me ka maikaʻi, nā mea ʻaleʻa, a me ka mālama ʻili.